Close
Novotech
Jabsco PureFlo 21 Single Use

Berry’s Dual Chamber Inhaler Enables Access to Combination Drugs

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

How Automation Is Transforming Mail-Order Pharmacy Operations: Efficiency, Accuracy and ROI

This article includes: Expanding the Role of Mail-Order Pharmacies ...

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.
- Advertisement -

Berry Global, a leader in the design, development, and production of patient-centred healthcare solutions, recently launched the BerryHaler, a dual chamber, dry powder inhaler (DPI) with a dose counter designed to provide better patient access to and support the effective delivery of combination drugs.

“The BerryHaler demonstrates our commitment to delivering patient-centred products for our pharmaceutical customers with customisable, off-the-shelf solutions that help bring new treatments to market quickly,” said Marco Franza, Sales and Business Development Director for Berry Global Healthcare. “By partnering with our experts, customers can reduce investment costs and
development time, relying on Berry for the device and focusing their resources on formulation development.”

The BerryHaler offers pharmaceutical companies a ready-to-use and customisable solution for the fast-to-market introduction of inhalation treatments that relieve the symptoms of Chronic Obstructive Pulmonary Disease (COPD), asthma, and other lung disorders. The patented design incorporates dual chamber Puck properties that enable the delivery of 30 doses of double and triple
formulations simultaneously to the patient.

The all-plastic inhaler with no metal parts is ideal for more complex inhalation treatments, including those that would otherwise require several different inhalers to achieve the correct dosage and combination drug treatments that cannot be combined in a single blend. Additionally, the BerryHaler provides easy and intuitive operation for various patient profiles, including seniors and children.
Special features include a bi-directional non-detachable mouthpiece cover that enhances ease of use and helps prevent cover loss, protecting the formulation and providing a more hygienic application for patients. The device also emits an audible signal when opening and closing the mouthpiece so that users know it has been fully opened for inhalation and then safely closed. The integrated dose
counter helps patients to accurately monitor medication usage and remaining doses and avoid accidental over-or underdosage.

The BerryHaler has been developed as part of Berry’s ‘Dose Better’ initiative, which is focused on the introduction of patient-centred packaging and drug delivery devices that deliver accurate and user- friendly dosing administration and support improved medicine adherence.

Latest stories

Related stories

How Automation Is Transforming Mail-Order Pharmacy Operations: Efficiency, Accuracy and ROI

This article includes: Expanding the Role of Mail-Order Pharmacies ...

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.

FDA Issues 3 Priority Vouchers for Psychedelic Drug Firms

The US Food and Drug Administration has awarded three...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »